ProCE Banner Activity

Steps Toward Precision Oncology: Role of SERDs in Attacking Endocrine Resistance in HR+/HER2- Breast Cancer

Slideset

Download these slides to review the most recent data on the rationale for and mechanism of action for oral SERDs therapy in HR+/HER2- breast cancer.

Released: May 30, 2024

Expiration: May 29, 2025

Share

Faculty

Aditya Bardia

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Lilly.

AstraZeneca

Lilly